Growth hormone treatment prevents loss of lean mass after bariatric surgery in morbidly obese patients: results of a pilot, open, prospective, randomized, controlled study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The loss of lean body mass (LBM) negatively influences the outcome in bariatric surgery.

Impaired GH secretion is frequent in obese patients.

Who Took Part

The study group was 24 women.

The age groups tagged for this paper are teenagers, adults and middle-aged adults, women only.

A total of 24 women (body mass index: 44.4 +/- 7.6 kg/m(2), aged 36.8 +/- 11.7 yr) undergoing laparoscopic-adjustable silicone gastric banding (LASGB) and with GH deficiency after LASGB was included in the study.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

This was an open, prospective, randomized, and controlled study.

What Was Measured

The loss of lean body mass (LBM) negatively influences the outcome in bariatric surgery.

PubMed files the paper under topics including Body Composition, Body Mass Index, Energy Metabolism, Gastroplasty, Human Growth Hormone, Insulin-Like Growth Factor I and Laparoscopy.

What This Means in Plain Language

The paper is a randomized and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 24 women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2009 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.